medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-19-120-124medsovet-5278Research ArticleКЛИНИЧЕСКОЕ НАБЛЮДЕНИЕCLINICAL OBSERVATIONКлинический случай многолетнего применения алектиниба в лечении ALK-позитивного НМРЛClinical case of prolonged use of alectinib in the treatment of ALK-positive NSCLChttps://orcid.org/0000-0003-2981-7666БагроваС. Г.BagrovaS. G.

к.м.н., научный сотрудник, онкологическое отделение лекарственных методов лечения (химиотерапевтическое) №1 

115478, Россия, Москва, Каширское шоссе, д. 23

Cand. of Sci. (Med.), Researcher, Oncology Drug Therapy (Chemotherapy) Department No. 1

23, Kashirskoe shosse, Moscow, 115478, Russia

s.bagrova@mail.ruhttps://orcid.org/0000-0002-6762-9511КоломейцеваА. А.KolomeytsevaA. A.

к.м.н., заведующая дневным стационаром

119121, Россия, Москва, ул. Погодинская, д. 6, стр. 1

Cand. of Sci. (Med.), Head of Day Patient Hospital, Outpatient Department

Bldg. 1, 6, Pogodinskaya St., Moscow, 119121, Russia

almed2002@mail.ruТрусиловаЕ. В.TrusilovaE. V.

к.м.н., научный сотрудник, онкологическое отделение лекарственных методов лечения (химиотерапевтическое) №1

115478, Россия, Москва, Каширское шоссе, д. 23

Cand. of Sci. (Med.), Researcher, Oncology Drug Therapy (Chemotherapy) Department No. 1

23, Kashirskoe shosse, Moscow, 115478, Russia

tev_86@mail.ruhttps://orcid.org/0000-0003-0703-2550ГорбуноваВ. А.GorbunovaV. A.

д.м.н., профессор, ведущий научный сотрудник, онкологическое отделение лекарственных методов лечения(химиотерапевтическое) №1

115478, Россия, Москва, Каширское шоссе, д. 23

Dr. of Sci. (Med.), Professor, Principal Researcher, Oncology Drug Therapy (Chemotherapy) Department No. 1

23, Kashirskoe shosse, Moscow, 115478, Russia

veragorbounova@mail.ruНациональный медицинский исследовательский центр онкологии имени Н.Н. БлохинаРоссияFederal State Budgetary Institution «Blokhin National Medical Research Cancer Centre» of the Ministry of Health of the Russian FederationRussian FederationПоликлиническое отделение Московского научно-исследовательского онкологического института им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииРоссияP. A. Hertsen Moscow Oncology Research Institute – Branch of Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Healthcare of the Russian FederationRussian Federation201906122019019120124Copyright © Багрова С.Г., Коломейцева А.А., Трусилова Е.В., Горбунова В.А., 20192019Багрова С.Г., Коломейцева А.А., Трусилова Е.В., Горбунова В.А.Bagrova S.G., Kolomeytseva A.A., Trusilova E.V., Gorbunova V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/5278немелкоклеточный рак легкоготранслокация ALKкризотинибалектинибnon-small cell lung cancerALK translocationalectinibcrizotinibReferencesShaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.J., De Pas T., Besse B., Solomon B.J., Blackhall F., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-2394. doi: 10.1056/NEJMoa1214886.Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.J., De Pas T., Besse B., Solomon B.J., Blackhall F., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-2394. doi: 10.1056/NEJMoa1214886.Tsao A.S., Scagliotti G.V., Bunn P.A. Jr, Carbone D.P., Warren G.W., Bai C., et al. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016;11(5):613-638. DOI: 10.1016/j.jtho.2016.03.012.Tsao A.S., Scagliotti G.V., Bunn P.A. Jr, Carbone D.P., Warren G.W., Bai C., et al. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016;11(5):613-638. DOI: 10.1016/j.jtho.2016.03.012.Novello S., Mazieres J., Oh I.J., de Castro J., Migliorino M.R., Helland A., et al. Primary Results from the Phase III ALUR Study of Alectinib versus Chemotherapy in Previously Treated ALK+Non-Small-Cell Lung Cancer (NSCLC). Annals of Oncology 2017;28(suppl_5):v605-v649. doi: 10.1093/annonc/mdx440.058.Novello S., Mazieres J., Oh I.J., de Castro J., Migliorino M.R., Helland A., et al. Primary Results from the Phase III ALUR Study of Alectinib versus Chemotherapy in Previously Treated ALK+Non-Small-Cell Lung Cancer (NSCLC). Annals of Oncology 2017;28(suppl_5):v605-v649. doi: 10.1093/annonc/mdx440.058.Kerr K.M., López-Ríos F. Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? Ann Oncol. 2016;27(Suppl 3):iii16-iii24. doi: 10.1093/annonc/mdw302.Kerr K.M., López-Ríos F. Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? Ann Oncol. 2016;27(Suppl 3):iii16-iii24. doi: 10.1093/annonc/mdw302.Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., Felip E., Cappuzzo F., Paolini J., Usari T., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167-2177. doi: 10.1056/NEJMoa1408440.Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., Felip E., Cappuzzo F., Paolini J., Usari T., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167-2177. doi: 10.1056/NEJMoa1408440.Duruisseaux M., Besse B., Cadranel J., Pérol M., Mennecier B., Bigay-Game L., Descourt R., Dansin E., Audigier-Valette C., Moreau L., et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive nonsmall-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8(13):21903-21917. doi: 10.18632/oncotarget.15746.Duruisseaux M., Besse B., Cadranel J., Pérol M., Mennecier B., Bigay-Game L., Descourt R., Dansin E., Audigier-Valette C., Moreau L., et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive nonsmall-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8(13):21903-21917. doi: 10.18632/oncotarget.15746.Peters S., Camidge D.R., Shaw A.T., Gadgeel S., Ahn J.S., Kim D.W. et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-SmallCell Lung Cancer. N Engl J Med. 2017;377(9):829-838. doi: 10.1056/NEJMoa1704795.Peters S., Camidge D.R., Shaw A.T., Gadgeel S., Ahn J.S., Kim D.W. et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-SmallCell Lung Cancer. N Engl J Med. 2017;377(9):829-838. doi: 10.1056/NEJMoa1704795.Shaw A.T., Gandhi L., Gadgeel S., Riely G. et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17(2):234-242. doi: 10.1016/S1470-2045(15)00488-X.Shaw A.T., Gandhi L., Gadgeel S., Riely G. et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17(2):234-242. doi: 10.1016/S1470-2045(15)00488-X.Ou S.H., Ahn J.S., De Petris L., Govindan R., Yang J.C., Hughes B., Lena H., Moro-Sibilot D., Bearz A., Ramirez S.V., et al. Alectinib in crizotinib-refractory ALK- rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol. 2016;34(7):661-668. doi: 10.1200/JCO.2015.63.9443.Ou S.H., Ahn J.S., De Petris L., Govindan R., Yang J.C., Hughes B., Lena H., Moro-Sibilot D., Bearz A., Ramirez S.V., et al. Alectinib in crizotinib-refractory ALK- rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol. 2016;34(7):661-668. doi: 10.1200/JCO.2015.63.9443.Gadgeel S.M., Ganghi L., Riely G.J., Chiappori A.A., West H.L., Azada M.C. et al. Safety and activity of alectenib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer: results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15(10):1119-1128. doi: 10.1016/S1470-2045(14)70362-6.Gadgeel S.M., Ganghi L., Riely G.J., Chiappori A.A., West H.L., Azada M.C. et al. Safety and activity of alectenib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer: results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15(10):1119-1128. doi: 10.1016/S1470-2045(14)70362-6.Реутова Е.В., Лактионов К.К. Новые возможности в лечении больных ALK-позитивным немелкоклеточным раком легкого. Онкология. Журнал им. П.А. Герцена. 2019;8(3):226-230. doi: 10.17116/onkolog2019803115226.Reutova E.V., Laktionov K.K. New opportunities in the treatment of patients with ALK-positive non-small cell lung cancer. Onkologiya. Zhurnal imeni P.A. Gertsena = P.A. Herzen Journal of Oncology. 2019;8(3):226-230. doi: 10.17116/onkolog2019803115226.Camidge D.R., Peters S., Mok T., Gadgeel S.M., Cheema P.K., Pavlakis N., Marinis F.D., Stroyakovskiy D.L., Cho B.C., Zhang L., et al. Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+NSCLC. ASCO 2018. Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9043.Camidge D.R., Peters S., Mok T., Gadgeel S.M., Cheema P.K., Pavlakis N., Marinis F.D., Stroyakovskiy D.L., Cho B.C., Zhang L., et al. Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+NSCLC. ASCO 2018. Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9043.Mok T.S.K., Shaw A.T., Camidge R.D., Gadgeel S.M., Rosell R., Dziadziuszko R., et al. Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. Annals of Oncology. 2019;30(Suppl_5):mdz260.006. doi: 10.1093/annonc/mdz260.006.Mok T.S.K., Shaw A.T., Camidge R.D., Gadgeel S.M., Rosell R., Dziadziuszko R., et al. Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. Annals of Oncology. 2019;30(Suppl_5):mdz260.006. doi: 10.1093/annonc/mdz260.006.

The authors declare that there are no conflicts of interest present.